CA-ULTRAVIOLET-DEVICES
14.1.2021 14:47:33 CET | Business Wire | Press release
UltraViolet Devices, Inc. (UVDI) announced its UVDI-360 Room Sanitizer achieved greater than 99.99%, or 4log10 , inactivation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in 5 minutes at a distance of 12 feet (3.65 meters). Testing on the coronavirus strain that causes the COVID-19 disease was conducted by Innovative Bioanalysis, a CAP, CLIA, and BEI-recognized BSL-3 certified laboratory (CA, USA). The Centers for Disease Control and Prevention (CDC) has indicated that the COVID-19 disease can be spread by both surface and airborne transmission of SARS-CoV-2.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005585/en/
The testing parameters were carefully selected to be indicative of rapid whole room disinfection in hospitals. The UVDI-360 Room Sanitizer has previously been proven to help prevent Healthcare-Associated Infections and to inactivate over 35 pathogens, including human coronavirus (229E), in over 10 peer-reviewed published clinical studies and independent laboratory testing.
“We hope this important testing can lend confidence and comfort to Healthcare professionals working bravely and tirelessly to beat COVID-19.” stated Peter Veloz, Chief Executive Officer, UVDI. “Specific to use in hospitals for whole room disinfection, we believe that proving rapid inactivation of pathogens at distances of 8 feet (2.44 meters) and 12 feet (3.65 meters) is the best marker for in-facility performance. Independent confirmation of effectiveness against high-risk pathogens is a common sense, yet critical step to verify disinfecting claims for UV devices.”
“Building on our deep science-based evidence demonstrating the UVDI-360’s effectiveness against high-risk pathogens, including coronaviruses, we feel the healthcare professionals we serve globally deserve proof against the specific SARS-CoV-2 viral strain causing COVID-19,” added Dr. Ashish Mathur, Vice President of Innovation and Technology, UVDI.
About UltraViolet Devices, Inc.
UVDI’s Mission is to make a cleaner, safer, and healthier world through advanced UV-C solutions that disinfect the air and surfaces in the environments we live, work, and play in. UVDI designs and manufactures advanced Ultraviolet light solutions in California, applying over 70 years and three generations of family craftsmanship and care. Over 2,000 UVDI-360 Room Sanitizers are used in approximately 1,000 leading hospitals in more than 25 countries, where it has been proven in peer-reviewed, published studies to reduce Healthcare-Associated Infections and inactivate high-risk pathogens. UVDI’s proven Indoor Air Quality solutions are now installed in over 10,000 International commercial sites. UVDI is proud to be a certified Minority Business Enterprise (MBE).
1 https://www.cdc.gov/coronavirus
View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005585/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom